NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.15 -0.10 (-1.38 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$7.15
Today's Range$7.15 - $7.35
52-Week Range$3.90 - $11.90
Volume53,935 shs
Average Volume103,713 shs
Market Capitalization$162.56 million
P/E Ratio-5.11
Dividend YieldN/A
Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.03
Current Ratio8.11
Quick Ratio8.11


Trailing P/E Ratio-5.11
Forward P/E Ratio-4.31
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.07 per share
Price / Book3.45


EPS (Most Recent Fiscal Year)($1.40)
Net Income$-22,340,000.00
Net MarginsN/A
Return on Equity-74.18%
Return on Assets-66.25%


Outstanding Shares20,980,000
Market Cap$162.56 million

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) issued its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.03. View Aldeyra Therapeutics' Earnings History.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

4 brokerages have issued 1 year price targets for Aldeyra Therapeutics' shares. Their predictions range from $13.00 to $27.00. On average, they expect Aldeyra Therapeutics' stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 169.2% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

What is the consensus analysts' recommendation for Aldeyra Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (8/14/2018)
  • 2. Canaccord Genuity analysts commented, "We are expecting a late 3Q18/early 4Q18 data update for the Phase 2b dry eye disease trial, which we are expecting to show changes across multiple standard signs and symptom endpoints. We remind investors that while statistical significance over vehicle (superiority) would be ideal, the trial is not powered to detect superiority since vehicle has not previously been tested against reproxalap. However, since the vehicle is an “aqueous” formulation, we do not expect significant activity from the vehicle arm. Furthermore, the data update would help us assess the proper dosing and endpoints (symptom and sign) for the Phase 3 trial. We remind investors that the FDA is likely to look for one replicated sign and one replicated symptom improvement as basis of approval." (8/10/2018)
  • 3. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and 12-month price target of $23/share, following Aldeyra Therapeutics’ Research day hosted June 26, 2018. The research day highlighted several additional compounds under investigation that deepen the company’s leadership in targeting of RASP (reactive aldehyde species that are pro-inflammatory) pathway, reproxalap, and broadening development efforts inhibiting heat shock protein 90 (HSP90). Over the next 12-18 months, we anticipate significant catalysts with reproxalap from an upcoming Phase 2b dry eye disease and three Phase 3 studies. We believe the earlier pipeline could generate additional data catalysts for the shares, following these reproxalap readouts." (6/26/2018)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

Has Aldeyra Therapeutics been receiving favorable news coverage?

Headlines about ALDX stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a media and rumor sentiment score of 0.01 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 48.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Aldeyra Therapeutics.

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.75%), Millennium Management LLC (3.46%), Russell Investments Group Ltd. (0.81%), Stanley Laman Group Ltd. (0.47%), Bank of New York Mellon Corp (0.24%) and Mesirow Financial Investment Management Inc. (0.20%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Which institutional investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Aldeyra Therapeutics.

Which institutional investors are buying Aldeyra Therapeutics stock?

ALDX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Mesirow Financial Investment Management Inc., Essex Investment Management Co. LLC, Stanley Laman Group Ltd., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Rhumbline Advisers. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $7.15.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $162.56 million. The biotechnology company earns $-22,340,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 12 workers across the globe.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.